Cargando…

Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome: Genetic Insights from EXPLORE-J

Aim: Genetic testing can provide a definitive diagnosis of familial hypercholesterolemia (FH). However, accessibility of genetic testing may be limited in certain countries where it is not considered “standard of care,” including Japan. In addition, mutations responsible for FH cannot be identified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada-Shiba, Mariko, Ako, Junya, Hirayama, Atsushi, Nakamura, Masato, Nohara, Atsushi, Sato, Kayoko, Murakami, Yoshitaka, Koshida, Ryusuke, Ozaki, Asuka, Arai, Hidenori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371751/ https://www.ncbi.nlm.nih.gov/pubmed/34526433 http://dx.doi.org/10.5551/jat.62989

Ejemplares similares

Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J
por: Nakamura, Masato, et al.
Publicado: (2021)

Investigation into Lipid Management in Acute Coronary Syndrome Patients from the EXPLORE-J Study
por: Nakamura, Masato, et al.
Publicado: (2019)

Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study
por: Nakamura, Masato, et al.
Publicado: (2017)

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Guidance for Pediatric Familial Hypercholesterolemia 2017
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017)

Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene
por: Tada, Hayato, et al.
Publicado: (2022)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
por: Nohara, Atsushi, et al.
Publicado: (2019)

What Arteries are Affected in Familial Hypercholesterolemia?
por: Harada-Shiba, Mariko
Publicado: (2019)

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Yamashita, Shizuya, et al.
Publicado: (2022)

Impact of Familial Hypercholesterolemia Diagnosis in Real-World Data
por: Harada-Shiba, Mariko
Publicado: (2023)

The Roles of Genetic Analysis in the Diagnosis of Pediatric Patients with Familial Hypercholesterolemia
por: Harada-Shiba, Mariko
Publicado: (2022)

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan
por: Teramoto, Tamio, et al.
Publicado: (2018)

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Ogura, Masatsune, et al.
Publicado: (2022)

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy
por: Kajinami, Kouji, et al.
Publicado: (2019)

Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Naito, Ryo, et al.
Publicado: (2022)

Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease
por: Tada, Hayato, et al.
Publicado: (2018)

Prevalent Coronary Artery Disease and Undertreatment in Heterozygous Familial Hypercholesterolemia -Real-World Data and “Heterozygous FH Score” from FAME Study-
por: Nohara, Atsushi
Publicado: (2022)

Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease
por: Katamine, Masahiro, et al.
Publicado: (2021)

The benign c.344G > A: p.(Arg115His) variant in the LDLR gene interpreted from a pedigree-based genetic analysis of familial hypercholesterolemia
por: Hori, Mika, et al.
Publicado: (2020)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
por: Teramoto, Tamio, et al.
Publicado: (2017)

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
por: Kataoka, Yu, et al.
Publicado: (2022)

What Can Be Seen From “Intracranial-Vascular”–Susceptibility Genetic Factor in “Cardiovascular-Susceptible” Familial Hypercholesterolemia: A New Clue
por: Nohara, Atsushi
Publicado: (2023)

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Kameyama, Noriko, et al.
Publicado: (2019)

Impact of the severe familial hypercholesterolemia status on atherosclerotic risks
por: Tada, Hayato, et al.
Publicado: (2023)

Sudden Cardiac Arrest in a Patient With Sarcoidosis and Familial Hypercholesterolemia
por: Sugimoto, Hiroshi, et al.
Publicado: (2021)

Acute Cholesterol-Lowering Effect of Exendin-4 inLdlr(−/−) and C57BL/6J Mice
por: Hori, Mika, et al.
Publicado: (2023)

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Oral Fat Tolerance Test for Sitosterolemia and Familial Hypercholesterolemia: A Study Protocol
por: Nomura, Akihiro, et al.
Publicado: (2018)

Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation　― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―
por: Nakao, Koichi, et al.
Publicado: (2022)

Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia
por: Michikura, Masahito, et al.
Publicado: (2022)

Relationship between platelet aggregation and stroke risk after percutaneous coronary intervention: a PENDULUM analysis
por: Matsumaru, Yuji, et al.
Publicado: (2022)

Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels
por: Funabashi, Sayaka, et al.
Publicado: (2022)

Impact of Healthy Lifestyle in Patients With Familial Hypercholesterolemia
por: Tada, Hayato, et al.
Publicado: (2023)

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
por: Ishii, Mitsuru, et al.
Publicado: (2022)

Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial
por: Matsuzawa, Yasushi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v2qs5v9snabm3scdvlh81v8ip9